ABVX ABIVAX Société Anonyme
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.…
Industry Peers
BiotechnologyKey Statistics
About ABIVAX (EPA: ABVX)
›
ABIVAX (EPA: ABVX) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 98 employees.
The shares were at 76.70 EUR on 19 November 2026, down 25.2% over 52 weeks. Its 52-week range is 60.45 EUR to 139.00 EUR: the price is 44.8% below the high and 26.9% above the low.
Its market capitalisation is 6.66B EUR.
ABIVAX reports return on equity of -73.8% and revenue down 6.8% year over year.
It holds more cash than debt, a net cash position of 401.17M EUR. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 7 analysts cover the stock, with an average rating of Buy; their mean price target of 131.72 EUR is 71.7% above the current price. The next earnings report is expected on 22 March 2027.